Alyeska Investment Group’s Unity Biotechnology UBX Stock Holding History

Alyeska Investment Group’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-292,091	Closed	-$304K	–	678
2025 Q1	$304K	Sell	292,091 -566,992	-66%	-$1.02M	﹤0.01%	481
2024 Q4	$839K	Sell	859,083 -60,930	-7%	-$75.7K	﹤0.01%	503
2024 Q3	$1.35M	Hold	920,013	–	–	0.01%	444
2024 Q2	$1.24M	Hold	920,013	–	–	0.01%	450
2024 Q1	$1.51M	Sell	920,013 -121,318	-12%	-$210K	0.01%	398
2023 Q4	$2.01M	Buy	1,041,331 +1,002,636	+2,591%	+$1.86M	0.01%	368
2023 Q3	$92.9K	Buy	+38,695	New	+$103K	﹤0.01%	469
2023 Q2	–	Sell	-38,695	Closed	-$102K	–	632
2023 Q1	$63.1K	Sell	38,695 -658,753	-94%	-$2.64M	﹤0.01%	440
2022 Q4	$1.91M	Sell	697,448 -588,552	-46%	-$1.71M	0.02%	321
2022 Q3	$5.08M	Buy	+1,286,000	New	+$8.11M	0.06%	267
2018 Q3	–	Sell	-7,588	Closed	-$1.14M	–	511
2018 Q2	$1.14M	Buy	+7,588	New	+$1.11M	0.01%	389

Other funds holding UBX

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's UBX Position: Q2 2025 in Review

Alyeska Investment Group sold out of Unity Biotechnology (UBX) in Q2 2025, closing a stake of 292,091 shares — an estimated $304K sold.

Alyeska Investment Group first reported a position in UBX in Q2 2018 and held it in 11 quarters. The position peaked at $5.08M in Q3 2022. 35 funds tracked by Wall St. Rank hold UBX as of Q2 2025.

Alyeska Investment Group reported no remaining Unity Biotechnology position as of Q2 2025 after selling out during the quarter.
Alyeska Investment Group sold 292,091 Unity Biotechnology shares in Q2 2025, an estimated $304K.
Alyeska Investment Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 11 quarters.
Alyeska Investment Group's Unity Biotechnology position peaked at $5.08M in Q3 2022.
35 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.